Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Oncolytics Biotech ( (TSE:ONC) ) just unveiled an announcement.
Oncolytics Biotech has received regulatory approval from Germany’s Paul-Ehrlich-Institute to proceed with the full enrollment of Cohort 5 in their GOBLET study, which evaluates the combination of pelareorep and mFOLFIRINOX, with or without atezolizumab, for pancreatic ductal adenocarcinoma patients. This approval follows a favorable safety review, and early safety data will be presented at the upcoming 2025 ASCO Symposium. The progression of this cohort could potentially expand treatment options for metastatic pancreatic cancer patients, significantly impacting Oncolytics’ position in the oncology market.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is engaged in clinical trials for treating various cancers, including metastatic breast cancer and pancreatic cancer, utilizing pelareorep’s ability to induce anti-cancer immune responses and enhance tumor inflammation.
YTD Price Performance: -12.90%
Average Trading Volume: 460,901
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $62.81M
For a thorough assessment of ONC stock, go to TipRanks’ Stock Analysis page.
